Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
Recruiting · NCT05876312 · Registry updated 2026-06-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients | Hemic and Lymphatic Diseases, Hemoglobinuria, Paroxysmal, anemia, bone marrow disorder, hematologic disorder, hemolytic anemia, myelodysplastic syndrome | Recruiting | Phase 1 / Phase 2 | 2026-06-16 | NCT05876312 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| ADARx Australia Pty Ltd | 2 |
| ADARx Pharmaceuticals, Inc. | 9 |
| Novotech (Australia) Pty Limited | 15 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Nucleus Network Brisbane | Brisbane | Australia | 3 |
| Peter MacCallum Cancer Centre | Melbourne | Australia | 149 |
| Richmond Pharmacology Ltd | London | United Kingdom | 1 |
| Royal Melbourne Hospital | Parkville | Australia | 5 |